First Tissue-Agnostic Drug Approval Issued

Overview

Journal Cancer Discov

Specialty Oncology

Date 2017 Jun 7

PMID 28583911

Citations 27

Affiliations

Soon will be listed here.

Abstract

The PD-1 inhibitor pembrolizumab received accelerated approval for adult and pediatric patients with solid tumors that are mismatch repair-deficient or microsatellite instability-high. This is the first time the FDA has greenlighted a drug based not on tumor type, but on a common biomarker.

Citing Articles

If it's a target, it's a pan-cancer target: Tissue is not the issue.

Adashek J, Kato S, Sicklick J, Lippman S, Kurzrock R Cancer Treat Rev. 2024; 125:102721.

PMID: 38522181 PMC: 11093268. DOI: 10.1016/j.ctrv.2024.102721.

Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.

Zhou I, Plana D, Palmer A Clin Cancer Res. 2023; 30(4):786-792.

PMID: 38109210 PMC: 10922532. DOI: 10.1158/1078-0432.CCR-23-0983.

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides.

Nejatie A, Yee S, Jeter A, Saragovi H Front Oncol. 2023; 13:1261090.

PMID: 37954075 PMC: 10637394. DOI: 10.3389/fonc.2023.1261090.

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.

Tao S, Liang S, Zeng T, Yin D Front Immunol. 2023; 13:1043667.

PMID: 36685594 PMC: 9845774. DOI: 10.3389/fimmu.2022.1043667.

Single-cell profiling to transform immunotherapy usage and target discovery in immune-mediated inflammatory diseases.

Chapelle N, Fantou A, Marron T, Kenigsberg E, Merad M, Martin J Front Immunol. 2022; 13:1006944.

PMID: 36420260 PMC: 9677096. DOI: 10.3389/fimmu.2022.1006944.